The effects of vagus nerve stimulation therapy on patients with intractable seizures and either Landau-Kleffner syndrome or autism

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Acquired and developmental comorbid conditions, including language and behavioral disorders, are often associated with epilesy. Although the relationship between these disorders is not fully understood, their close association may indicate that they share common features, suggesting that these conditions may respond to the same therapies. Not only has vagus nerve stimulation (VNS) therapy been proven to reduce the frequency of pharmacoresistant seizures in epilepsy patients, but preliminary studies also indicate that VNS therapy may improve neurocognitive performance. On the basis of these findings, we hypothesized that VNS therapy would improve the quality of life of patients with either Landau-Meffner syndrome (LKS) or autism, independent of its effects on seizures. Data were retrospectively queried from the VNS therapy patient outcome registry (Cyberonics, Inc; Houston, TX, USA). A constant cohort of 6 LKS patients and 59 autistic patients were identified. Among the LKS patients, 3 patients at 6 months experienced at least a 50% reduction in seizure frequency as compared with baseline. Physicians reported quality-of-life improvements in all areas assessed for at least 3 of the 6 children. More than half of the patients with autism (58%) experienced at least a 50% reduction in seizure frequency at 12 months. Improvements in all areas of quality of life monitored were reported for most patients, particularly for alertness (76% at 12 months). Although these preliminary findings are encouraging, a prospective study using standardized measurement tools specific to these disorders and a longer-term follow-up are necessary to better gauge the efficacy of VNS therapy among these patient populations.

Original languageEnglish (US)
Pages (from-to)286-290
Number of pages5
JournalEpilepsy and Behavior
Volume4
Issue number3
DOIs
StatePublished - Jan 1 2003

Fingerprint

Landau-Kleffner Syndrome
Vagus Nerve Stimulation
Autistic Disorder
Seizures
Therapeutics
Quality of Life
Language Disorders
Quality Improvement
Registries
Epilepsy

Keywords

  • Autism
  • Behavioral disorders
  • Epilepsy
  • Intractable seizures
  • Landau-Kleffner syndrome
  • Language disorders
  • Pharmacoresistant epilepsy
  • Vagus nerve stimulation therapy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Cite this

@article{153cc5a726b444ea991b67a53bdfd249,
title = "The effects of vagus nerve stimulation therapy on patients with intractable seizures and either Landau-Kleffner syndrome or autism",
abstract = "Acquired and developmental comorbid conditions, including language and behavioral disorders, are often associated with epilesy. Although the relationship between these disorders is not fully understood, their close association may indicate that they share common features, suggesting that these conditions may respond to the same therapies. Not only has vagus nerve stimulation (VNS) therapy been proven to reduce the frequency of pharmacoresistant seizures in epilepsy patients, but preliminary studies also indicate that VNS therapy may improve neurocognitive performance. On the basis of these findings, we hypothesized that VNS therapy would improve the quality of life of patients with either Landau-Meffner syndrome (LKS) or autism, independent of its effects on seizures. Data were retrospectively queried from the VNS therapy patient outcome registry (Cyberonics, Inc; Houston, TX, USA). A constant cohort of 6 LKS patients and 59 autistic patients were identified. Among the LKS patients, 3 patients at 6 months experienced at least a 50{\%} reduction in seizure frequency as compared with baseline. Physicians reported quality-of-life improvements in all areas assessed for at least 3 of the 6 children. More than half of the patients with autism (58{\%}) experienced at least a 50{\%} reduction in seizure frequency at 12 months. Improvements in all areas of quality of life monitored were reported for most patients, particularly for alertness (76{\%} at 12 months). Although these preliminary findings are encouraging, a prospective study using standardized measurement tools specific to these disorders and a longer-term follow-up are necessary to better gauge the efficacy of VNS therapy among these patient populations.",
keywords = "Autism, Behavioral disorders, Epilepsy, Intractable seizures, Landau-Kleffner syndrome, Language disorders, Pharmacoresistant epilepsy, Vagus nerve stimulation therapy",
author = "Park, {Yong D}",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S1525-5050(03)00080-5",
language = "English (US)",
volume = "4",
pages = "286--290",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - The effects of vagus nerve stimulation therapy on patients with intractable seizures and either Landau-Kleffner syndrome or autism

AU - Park, Yong D

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Acquired and developmental comorbid conditions, including language and behavioral disorders, are often associated with epilesy. Although the relationship between these disorders is not fully understood, their close association may indicate that they share common features, suggesting that these conditions may respond to the same therapies. Not only has vagus nerve stimulation (VNS) therapy been proven to reduce the frequency of pharmacoresistant seizures in epilepsy patients, but preliminary studies also indicate that VNS therapy may improve neurocognitive performance. On the basis of these findings, we hypothesized that VNS therapy would improve the quality of life of patients with either Landau-Meffner syndrome (LKS) or autism, independent of its effects on seizures. Data were retrospectively queried from the VNS therapy patient outcome registry (Cyberonics, Inc; Houston, TX, USA). A constant cohort of 6 LKS patients and 59 autistic patients were identified. Among the LKS patients, 3 patients at 6 months experienced at least a 50% reduction in seizure frequency as compared with baseline. Physicians reported quality-of-life improvements in all areas assessed for at least 3 of the 6 children. More than half of the patients with autism (58%) experienced at least a 50% reduction in seizure frequency at 12 months. Improvements in all areas of quality of life monitored were reported for most patients, particularly for alertness (76% at 12 months). Although these preliminary findings are encouraging, a prospective study using standardized measurement tools specific to these disorders and a longer-term follow-up are necessary to better gauge the efficacy of VNS therapy among these patient populations.

AB - Acquired and developmental comorbid conditions, including language and behavioral disorders, are often associated with epilesy. Although the relationship between these disorders is not fully understood, their close association may indicate that they share common features, suggesting that these conditions may respond to the same therapies. Not only has vagus nerve stimulation (VNS) therapy been proven to reduce the frequency of pharmacoresistant seizures in epilepsy patients, but preliminary studies also indicate that VNS therapy may improve neurocognitive performance. On the basis of these findings, we hypothesized that VNS therapy would improve the quality of life of patients with either Landau-Meffner syndrome (LKS) or autism, independent of its effects on seizures. Data were retrospectively queried from the VNS therapy patient outcome registry (Cyberonics, Inc; Houston, TX, USA). A constant cohort of 6 LKS patients and 59 autistic patients were identified. Among the LKS patients, 3 patients at 6 months experienced at least a 50% reduction in seizure frequency as compared with baseline. Physicians reported quality-of-life improvements in all areas assessed for at least 3 of the 6 children. More than half of the patients with autism (58%) experienced at least a 50% reduction in seizure frequency at 12 months. Improvements in all areas of quality of life monitored were reported for most patients, particularly for alertness (76% at 12 months). Although these preliminary findings are encouraging, a prospective study using standardized measurement tools specific to these disorders and a longer-term follow-up are necessary to better gauge the efficacy of VNS therapy among these patient populations.

KW - Autism

KW - Behavioral disorders

KW - Epilepsy

KW - Intractable seizures

KW - Landau-Kleffner syndrome

KW - Language disorders

KW - Pharmacoresistant epilepsy

KW - Vagus nerve stimulation therapy

UR - http://www.scopus.com/inward/record.url?scp=0141726862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141726862&partnerID=8YFLogxK

U2 - 10.1016/S1525-5050(03)00080-5

DO - 10.1016/S1525-5050(03)00080-5

M3 - Article

C2 - 12791330

AN - SCOPUS:0141726862

VL - 4

SP - 286

EP - 290

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

IS - 3

ER -